Literature DB >> 29573212

Medication use in infants admitted with bronchiolitis.

Ed Oakley1,2,3, Trusha Brys1, Meredith Borland4,5, Jocelyn Neutze6, Natalie Phillips7,8,9, David Krieser2,3,10, Stuart R Dalziel11,12, Andrew Davidson2,3,13, Susan Donath2,3, Kim Jachno2, Mike South2,3,14, Amanda Williams1,2, Franz E Babl1,2,3.   

Abstract

BACKGROUND: There are no medications known that improve the outcome of infants with bronchiolitis. Studies have shown the management of bronchiolitis to be varied.
OBJECTIVES: To describe medication use at the seven study hospitals from a recent multi-centre randomised controlled trial on hydration in bronchiolitis (comparative rehydration in bronchiolitis [CRIB]).
METHODS: A retrospective analysis of extant data of infants between 2 months (corrected for prematurity) and 12 months of age admitted with bronchiolitis identified through the CRIB trial. CRIB study records, medical records, pathology and radiology databases were used to collect data using a standardised form and entered in a single site database. Medications investigated included salbutamol, adrenaline, steroids, ipratropium bromide, normal saline, hypertonic saline, steroids and antibiotics.
RESULTS: There were 3456 infants available for analysis, of which 42.0% received at least one medication during hospitalisation. Medication use varied by site between 27.0 and 48.7%. The most frequently used medication was salbutamol (25.5%). Medication use in general, and salbutamol use in particular, increased by 8.2 and 9.3%, respectively, per month after 4 months of age; from 22.9 and 3.6% at 4 months to 81.4 and 68.8% at 11 months. In infants admitted to the intensive care unit (ICU) compared with those not admitted to ICU 81.6 and 39.5%, respectively, received medication at one point during the hospital stay.
CONCLUSIONS: Medication was used for infants with bronchiolitis frequently and variably in Australia and New Zealand. Medication use increased with age. Better strategies for translating evidence into practice are needed.
© 2018 Australasian College for Emergency Medicine and Australasian Society for Emergency Medicine.

Entities:  

Keywords:  antibiotics; bronchiolitis; medication; salbutamol; steroids

Mesh:

Substances:

Year:  2018        PMID: 29573212     DOI: 10.1111/1742-6723.12968

Source DB:  PubMed          Journal:  Emerg Med Australas        ISSN: 1742-6723            Impact factor:   2.151


  6 in total

1. 

Authors:  David Greenky; Ran D Goldman
Journal:  Can Fam Physician       Date:  2022-06       Impact factor: 3.025

2. 

Authors:  David Greenky; Ran D Goldman
Journal:  Can Fam Physician       Date:  2022-06       Impact factor: 3.025

3.  Process evaluation of a cluster randomised controlled trial to improve bronchiolitis management - a PREDICT mixed-methods study.

Authors:  Libby Haskell; Emma J Tavender; Sharon O'Brien; Catherine L Wilson; Franz E Babl; Meredith L Borland; Rachel Schembri; Francesca Orsini; Elizabeth Cotterell; Nicolette Sheridan; Ed Oakley; Stuart R Dalziel
Journal:  BMC Health Serv Res       Date:  2021-11-29       Impact factor: 2.655

4.  Sustainability of evidence-based practices in the management of infants with bronchiolitis in hospital settings - a PREDICT study protocol.

Authors:  Victoria Ramsden; Franz E Babl; Stuart R Dalziel; Sandy Middleton; Ed Oakley; Libby Haskell; Anna Lithgow; Francesca Orsini; Rachel Schembri; Alexandra Wallace; Catherine L Wilson; Elizabeth McInnes; Peter H Wilson; Emma Tavender
Journal:  BMC Health Serv Res       Date:  2022-08-29       Impact factor: 2.908

5.  Treatment for acute bronchiolitis before and after implementation of new national guidelines: a retrospective observational study from primary and secondary care in Oslo, Norway.

Authors:  Nicolai Klem; Håvard Ove Skjerven; Beate Nilsen; Mette Brekke; Odd Martin Vallersnes
Journal:  BMJ Paediatr Open       Date:  2021-05-20

6.  Development of targeted, theory-informed interventions to improve bronchiolitis management.

Authors:  Libby Haskell; Emma J Tavender; Catherine L Wilson; Sharon O'Brien; Franz E Babl; Meredith L Borland; Elizabeth Cotterell; Nicolette Sheridan; Ed Oakley; Stuart R Dalziel
Journal:  BMC Health Serv Res       Date:  2021-08-03       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.